Sandbox Reserved 1705: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 19: Line 19:


== Applications ==
== Applications ==
Anaplastic lymphoma kinase's involvement as a proto-oncogene in various types of cancers has made it a target for drug therapies for these types of cancers <ref name="Lewis">PMID:22734674</ref>. One therapeutic medication that has been increasingly used with high levels of success is <scene name='90/904309/Crizotinib/1'>Crizotinib</scene>. This medication was approved by the FDA in January of 2021 for the treatment of pediatric/young adult ALK-positive anaplastic large cell lymphoma. The treatment has an overall response rate of 90%. Crizotinib works by <scene name='90/904309/Kinase_crizotinib/1'>binding</scene> to the ATP binding site of the <scene name='90/904309/Kinase_domain/1'>kinase domain</scene> <ref name="Sahu">PMID:24455567</ref>. Crizotinib binds preferentially to ATP in this region and therefore can effectively block the binding of ATP <ref name="Sahu" />. With the binding of ATP being blocked, the intercellular signaling cascade cannot begin which works to prevent the cancer from growing and spreading .   
Anaplastic lymphoma kinase's involvement as a proto-oncogene in various types of cancers has made it a target for drug therapies for these types of cancers <ref name="Lewis">PMID:22734674</ref>. One therapeutic medication that has been increasingly used with high levels of success is <scene name='90/904309/Crizotinib/1'>Crizotinib</scene>. This medication was approved by the FDA in January of 2021 for the treatment of pediatric/young adult ALK-positive anaplastic large cell lymphoma. The treatment has an overall response rate of 90%. Crizotinib works by <scene name='90/904309/Kinase_crizotinib/1'>binding</scene> to the ATP binding site of the <scene name='90/904309/Kinase_domain/1'>kinase domain</scene> <ref name="Sahu">PMID:24455567</ref>. Crizotinib binds preferentially to ATP in this region and therefore can effectively block the binding of ATP <ref name="Sahu" />. With the binding of ATP being blocked, the intercellular signaling cascade cannot begin which works to prevent cancerous cells from growing and spreading .   


</StructureSection>
</StructureSection>

Revision as of 13:50, 29 March 2022

This Sandbox is Reserved from February 28 through September 1, 2022 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1700 through Sandbox Reserved 1729.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Anaplastic Lymphoma Kinase

Drag the structure with the mouse to rotate

References


Student Contributors

  • Kaylin Todor
  • Rebekah White